Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Vertex Pharma's £1.65 million ($ ... access scheme and with a confidential discount. The CRISPR-based therapy will be an option for SCD patients aged 12 years and over who have at least two ...

After failing to find a commercial partner for its ex vivo CRISPR ... Vertex and CRISPR Therapeutics' rival Casgevy (exagamglogene autotemcel or exa-cel), which is already approved for SCD and ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

“2024 marked a year of tremendous growth for Vertex and we anticipate ... ex vivo, CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT that has been shown to reduce ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.